Impact of Her-2-targeted therapy on overall survival in patients with her-2 positive metastatic breast cancer

Breast Journal

Volumn 19, Issue 2, 2013, Pages 149-155

  Berghoff, Anna S ^a   Bago Horvath, Zsuzsanna ^a   Dubsky, Peter ^a   Rudas, Margaretha ^a   Pluschnig, Ursula ^a   Wiltschke, Christoph ^a   Gnant, Michael ^a   Steger, Guenther G ^a   Zielinski, Christoph C ^a   Bartsch, Rupert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

beyond progression; brain metastases; lapatinib; palliative therapy; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84874738840     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12070     Document Type: Article

References (27)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Slamon DJ, Godolphin W, Jones LA, et al,. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
3. Slamon DJ, Leyland-Jones B, Shak S, et al,. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
4. Clynes RA, Towers TL, Presta LG, Ravetch JV,. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
5. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ,. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-80.
6. Nagata Y, Lan KH, Zhou,. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-27.
7. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ,. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17: 2235-49.
8. Bartsch R, Wenzel C, Hussian D, et al,. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006; 6: 63.
9. Bartsch R, Wenzel C, Altorjai G, et al,. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25: 3853-8.
10. Bartsch R, Wenzel C, Gampenrieder SP, et al,. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 903-10.
11. von Minckwitz G, du Bois A, Schmidt M, et al,. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
12. von Minckwitz G,. Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Breast Cancer Progressing during Trastuzumab Treatment, in San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, 2010.
13. Cameron D, Casey M, Press M, et al,. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-43.
14. Blackwell KL, Burstein HJ, Storniolo AM, et al,. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. J Clin Oncol, 2010; 28: 1124-30.
15. Clayton AJ, Danson S, Jolly S, et al,. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-43.
16. Geyer CE, Forster J, Lindquist D, et al,. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
17. Bartsch R, Wenzel C, Pluschnig U, et al,. Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). J Clin Oncol, 2009; 27:15s, (suppl; abstr 1090).
18. Kiely BE, Soon YY, Tattersall MH, Stockler MR,. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011; 29: 456-63.
19. Montemurro F, Redana S, Viale G, et al,. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer 2008; 8: 436-42.
20. Bartsch R, De Vries C, Pluschnig U, et al,. Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer 2009; 9: 367.
21. Musolino A, Naldi N, Bortesi B, et al,. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-96.
22. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW,. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008; 107: 309-30.
23. Bundred NJ,. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001; 27: 137-42.
24. Pestalozzi BC, Zahrieh D, Price KN, et al,. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-44.
25. Hernan R, Fasheh R, Calabrese C, et al,. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003; 63: 140-8.
26. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE,. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15: 924-34.
27. Tripathy D, Slamon DJ, Cobleigh M, et al,. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-70.